<ul><li>Shares of Dr Reddy’s Laboratories rose over 3% in early trade on Tuesday after the company denied reports claiming it was undertaking a 25% reduction in workforce costs through large-scale layoffs.</li><li>Dr Reddy’s called the Business Standard report on senior-level exits and cost trimming ‘factually incorrect’.</li><li>The news report linked the alleged cost-cutting to margin pressures from Dr Reddy’s generic version of Revlimid and underperformance in newer ventures such as nutraceuticals and digital therapeutics.</li><li>Dr. Reddy's stock rose as much as 3.45% during the day to Rs 1,147.80 apiece on the NSE.</li></ul>

Dr. Reddy’s Share Price Rises 3% As Firm Dismisses Report On Job Cuts

Discover more